Latest Conference Articles

July 30th 2022, 6:51pm

International Lung Cancer Congress

Roy S. Herbst, MD, PhD, discusses the importance of evaluating ways of altering tumor host factors to improve response to immunotherapy in patients with lung cancer.

July 30th 2022, 3:05pm

International Lung Cancer Congress

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.

July 30th 2022, 2:50pm

International Lung Cancer Congress

Lyudmila A. Bazhenova, MD, discusses NTRK inhibition with larotrectinib and entrectinib in patients with NTRK fusion–positive non–small cell lung cancer.

July 30th 2022, 2:00pm

International Lung Cancer Congress

Daniel Morgensztern, MD, discusses updates on the investigation of bispecific antibodies and bispecific T-cell engagers in non–small cell lung cancer and small cell lung cancer.

July 30th 2022, 12:00pm

International Lung Cancer Congress

Jonathan Wesley Riess, MD, MS, discusses a phase 1 trial examining the combination of sapanisertib and telaglenastat, and explains why glutaminase inhibition is being investigated as a novel way to treat select patients with non–small cell lung cancer.

July 30th 2022, 10:00am

International Congress on the Future of Breast Cancer West

Nicholas P. McAndrew, MD, MSCE, discusses considerations to take when examining the relationship between chemotherapy, ovarian function suppression, and treatment benefits experienced by patients with hormone receptor–positive, HER2-negative breast cancer.

July 29th 2022, 10:43pm

International Congress on the Future of Breast Cancer West

Sara A. Hurvitz, MD, explains when de-escalation therapy can play a role in patients with HER2-positive breast cancer.

July 29th 2022, 9:21pm

International Lung Cancer Congress

Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer harboring EGFR mutations.

July 29th 2022, 9:00pm

International Congress on the Future of Breast Cancer West

Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

July 29th 2022, 9:00pm

International Congress on the Future of Breast Cancer West

Nicholas P. McAndrew, MD, MSCE, discusses the relationship between chemotherapy and ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

July 29th 2022, 9:00pm

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

July 29th 2022, 8:53pm

International Lung Cancer Congress

PD-L1 and tumor mutational burden are established biomarkers for leveraging immunotherapy in non–small cell lung cancer; however, their use may not be appropriate in determining treatment decisions for all patients.

July 29th 2022, 8:48pm

International Lung Cancer Congress

With two highly selective and active RET inhibitors approved for use in patients with metastatic RET alteration–positive non–small cell lung cancer, the dilemma is not determining which agent to select but ensuring that next-generation sequencing is done up front and in the presence of acquired resistance.

July 29th 2022, 5:15pm

International Lung Cancer Congress

Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.

July 29th 2022, 4:27pm

International Congress on the Future of Breast Cancer West

Aditya Bardia, MD, MPH, discusses recent and ongoing trials evaluating oral SERDs in estrogen receptor–positive breast cancer, the effect of ESR1 mutations on treatment efficacy, and how the use of ctDNA continues to evolve across the breast cancer space.

July 29th 2022, 3:37pm

International Lung Cancer Congress

Antibody-drug conjugates have demonstrated substantial activity in patients with HER2-mutated non–small cell lung cancer, with fam-trastuzumab deruxtecan-nxki showcasing the strongest response rate and progression-free survival benefit to date.

July 28th 2022, 10:44pm

International Lung Cancer Congress

David R. Gandara, MD, discusses the evaluation of tumor biomarkers in non–small cell lung cancer.

July 28th 2022, 10:41pm

International Lung Cancer Congress

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in EGFR exon 20–mutated non–small cell lung cancer.

July 28th 2022, 10:23pm

Traditional predictive biomarkers for the efficacy of peri-operative immunotherapy for patients with advanced non–small cell lung cancer, such as PD-L1 expression, still hold value but newer biomarker candidates such as minimal residual disease are starting to make an impact.

July 28th 2022, 10:22pm

International Lung Cancer Congress

Ignacio I. Wistuba, MD, explains how major pathological response and pathological complete response should be interpreted and their role as clinical end points.